Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2001 / Cilt: 27 - Sayı: 3

The evaluation of the efficiency of alfuzosin on dynamic component in benign prostatic hyperplasia by transrectal Doppler ultrasonography

Benin(selim) prostat hiperplazisinde alfuzosinin dinamik komponent üzerine etkinliğinin transrektal Doppler ultrasonografisi ile değerlendirilmesi

Pages
345–349
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result of transrectal Doppler ultrasonography evaluation, we propose that the alpha-blocker alfuzosin is efficient to decrease intraprostatic pressure and measurement of the resistivite index and central end diastolic velocity can be used to evaluate dynamic component of the prostate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study is to evaluate the effect of alfuzosin, which is a selective alpha Mocker on intraprostatic pressure by transrectal Doppler ultrasonography and if it is possible to use intraprostatic pressure as a dynamic parameter.
📊
Key Findings & Data:After this examination, the patients were subscribed Alfuzosin tb 7.5 mg/day for 15 days.
💡
Conclusion & Impact:As a result of transrectal Doppler ultrasonography evaluation, we propose that the alpha-blocker alfuzosin is efficient to decrease intraprostatic pressure and measurement of the resistivite index and central end diastolic velocity can be used to evaluate dynamic component of the prostate.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Basınç · İlaç uygulama programı · İlaç tedavisi

Abstract

The aim of this study is to evaluate the effect of alfuzosin, which is a selective alpha Mocker on intraprostatic pressure by transrectal Doppler ultrasonography and if it is possible to use intraprostatic pressure as a dynamic parameter. The urology outpatients applied with prostatic complaints were subjected to detailed history, international prostatic symptom score (IPSS), physical examination, routine biochemical examination and uroflowmetric evaluation. Twenty-seven patients diagnosed as benign prostatic hyperplasia (BPH) were evaluated by transrectal Doppler ultrasonography. After this examination, the patients were subscribed Alfuzosin tb 7.5 mg/day for 15 days. At the end of the treatment period, IPSS evaluation, uroflowmetry and transrectal Doppler ultrasonography were repeated. The mean age of the 27 patients was 61.70$\pm$7.51 (45-73). The mean $\pm$SEM IPSS, Qmax and Qave values of the patients before treatment were 14.16$\pm$1.19, 13.84$\pm$1.51 and 6.05$\pm$0.66 respectively whereas they were 9.44$\pm$0.44,16.45$\pm$1.25 and 7.36$\pm$0.72 after treatment. The uroflowmetry values before and after treatment were statistically different (p<0.05). Central end diastolic velocity (CEDV) and central resistivite index (CRI) were 4.3010.54 and 0.69$\pm$0.018 before treatment and they were 4.73$\pm$0.60 and 0.65$\pm$0.020 after treatment by transrectal Doppler ultrasonography. These results were statistically significant. There was no statistically significant difference in other parameters measured from central and peripheral zones (p>0.05). As a result of transrectal Doppler ultrasonography evaluation, we propose that the alpha-blocker alfuzosin is efficient to decrease intraprostatic pressure and measurement of the resistivite index and central end diastolic velocity can be used to evaluate dynamic component of the prostate.

Özet

Selektif alfa bloker olan alfuzosinin intraprostatik basınç üzerine etkisi ve intraprostatik basıncın dinamik parametre olarak kullanılıp kullanılamayacağının transrektal Doppler ultrasonografi ile değerlendirilmesi amaçlandı. Üroloji polikliniğine prostatizm şikayetleri ile başvuran olgulara öncelikle detaylı anamnez, uluslararası prostat semptom skoru (IPSS), fizik muayene, rutin biyokimyasal inceleme ve üroflovmetrik değerlendirme yapıldı. Selim (Benin) prostat hiperplazisi (BPH) tanısı alan 27 olguya transrektal Doppler ultrasonografi yapıldı. Bu incelemeden hemen sonra 15 gün süreyle Alfuzosin tb 7.5mg/gün başlandı. Tedavi süresi sonunda olguların IPSS, uroflovmetri ve transrektal Doppler ultrasonografi değerlendirmeleri tekrarlandı. Çalışmaya alınan 27 olgunun ortalama yaşı 61.70±7.51(45-73) idi. Olguların tedavi öncesi ortalama (±SEM) IPSS, Qmaks ve Qort değerleri sırasıyla 14.16±1.19, 13.84±1.51 ve 6.0510.66 iken tedavi sonrası 9.44±0.44, 16.45±1.25 ve 7.36±0.72 idi. Tedavi öncesi ve sonrası uroflovmetri değerleri arasındaki fark istatistiksel olarak anlamlı idi (p 0.05). TDU ile yapılan değerlendirmede alfa bloker olan alfuzosin intraprostatik basıncı düşürmede etkin olduğu ve resistivite indeksi ile santral end diyastolik akım hızının ölçülmesinin prostat dinamik komponentinin değerlendirilmesi için kullanılabileceği düşüncesindeyiz.

🔖

Cite This Article

DÜNDAR, M., KOÇAK, İ., TAŞKIN, E., BEDER, N., KARAMAN, C. (2001). The evaluation of the efficiency of alfuzosin on dynamic component in benign prostatic hyperplasia by transrectal Doppler ultrasonography. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 27 - Sayı: 3, 345–349. https://ajindex.com/articles/328881

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Fowler FJ, Wennberg JE, Timoty RP, et al: Symptom status and quality of life following prostatectomy. JAMA 259: 3018-3022, 1988 2- The Italian Alfuzosin Cooperative Group: Multi-center observational trial on symptomatic treatment of benign prostatic hyperplasia with al-fuzosin. Clinical evaluation of impact of patient's quality of life. Eur Urol 27: 128-134, 1995 3- Cockett ATK, Khoury S, Aso Y, et al: Procee-dings of the 3rd International Consultation on be-nign prostatic hyperplasia. Channel Islands, Sci-entific Communication International Ltd, pp: 1-651, 1995. 4- Tammela TLJ, Kontturi MJ: Urodynamic ef-fects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyper-plasia. J Urol 342: 342-344, 1993 5- Lepor H: Medical therapy for BPH. Urology 42: 483-502, 1993. 6- Lefevre-Borg F, O'Connor SE, Schomaker H, et al: Alfuzosin, a selective α1-adrenoceptor anta-gonist in the lower urinary tract. Br J Pharmacol 109: 1282-1289, 1993 7- Wilde MI, Fitton A, McTavish D: Alfuzosin: A review of its pharmacodynamic and pharmacoki-netic properties and therapeutic potential in be-nign prostatic hyperplasia. Drugs 45: 410-429, 1993 8- Neumaier CE, Martinoli C, Derchi LE, et al: Normal prostate gland: Examination with color Doppler US. Radiology 196: 453-457, 1995 9- Rubin JM, Bude RO, Carson PL, et al: Power Doppler US. A potentially useful alternative to mean frequency based color Doppler sonography. Radiology 190: 853-856, 1994 10- Kojima M, Watanabe H, Watanabe M, et al: Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med Bi-ol 23: 1305-1309, 1997 11- Okihara K, Kojima M, Naya Y, et al: Ultraso-nic power Doppler imaging for prostate cancer. A preliminary report. Tohoku J Exp Med 182: 277-281, 1997 12- Kojima M, Ochiai A, Naya Y, et al: Doppler re-sistive index in benign prostatic hyperplasia: Cor-relation with ultrasonic appearance of the prostate and infravesical obstruction. Eur Urol 37: 436-442, 2000 13- Caine M: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hy-pertrophy. J Urol 136: 1-4, 1986 14- Shapiro E, Becich MJ, Hartanto V, et al: The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147: 1293-1297, 1992 15- Hieble JP, Caine M, Zalaznik E: In vitro cha-racterization of the α-adrenoceptors in human prostate. Eur J Pharmacol 107: 111-117, 1985 16- Caine M, Ra